Dr. Lyle Oberg Appointment as Board Chair of Alberta Health Services and Executive Chair of MYND Life Sciences
Dr. Lyle Oberg Appointment as Board Chair of Alberta Health Services and Executive Chair of MYND Life Sciences
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), We are delighted to announce the appointment of Mynd Life Sciences current CEO and Director, the Hon. Dr. Lyle Oberg, E.C.A., as the Board Chair of Alberta Health Services (AHS). Dr. Oberg brings a distinguished career in both private practice and public service, having served as Minister of Alberta Learning, Finance, Infrastructure and Transportation, and Social Services. Previously appointed as a board member of the Alberta College of Physicians and Surgeons, Dr. Oberg's new role reflects his qualifications, expertise, and commitment to enhancing the quality of life for Albertans. Alberta Health Services, with approximately 125,000 employees and an annual budget of $16.5 billion, stands as one of Canada's most significant organizations. Dr. Oberg's well-deserved appointment underscores his leadership capabilities.
不列顛哥倫比亞省溫哥華--（新聞文件公司-2023 年 12 月 4 日）- MYND 生命科學 （案例：MYND）（OTCQB：MYNDF）（”MYND“或者”公司“），我們很高興地宣佈，Mynd Life Sciences現任首席執行官兼董事、E.C.A. Lyle Oberg博士閣下被任命爲艾伯塔省衛生服務部（AHS）董事會主席。奧伯格博士在私人執業和公共服務領域擁有傑出的職業生涯，曾擔任艾伯塔省學習、財政、基礎設施和交通以及社會服務部長。奧伯格博士此前曾被任命爲艾伯塔省內科和外科醫師學院的董事會成員，他的新職位反映了他的資格、專業知識和對提高艾伯塔人生活質量的承諾。艾伯塔省衛生服務部擁有約12.5萬名員工，年度預算爲165億加元，是加拿大最重要的組織之一。奧伯格博士當之無愧的任命凸顯了他的領導能力。
Concurrently, Mynd announces that Dr. Oberg will transition from the role of CEO to Executive Chairman of the Board, effective immediately. Since founding Mynd in 2021, Dr. Oberg has played a pivotal role in the company's growth, making it Canada's leader in the application of molecularly defined analogues of non-hallucinogenic psilocybins for therapeutic purposes. Under his visionary leadership, Mynd has initiated multiple preclinical and clinical trials to assess the efficacy of its technologies.
同時，Mynd宣佈，Oberg博士將從首席執行官一職轉爲董事會執行主席，立即生效。自2021年創立Mynd以來，Oberg博士在公司的發展中發揮了關鍵作用，使其成爲加拿大在將非致幻裸蓋菇素的分子定義類似物應用於治療目的方面的領導者。在他富有遠見的領導下，Mynd啓動了多項臨床前和臨床試驗，以評估其技術的功效。
In his new role as Executive Chairman, Dr. Oberg will focus on shaping the company's future, emphasizing strategy, strategic partnerships, acquisitions, and corporate governance. He will also serve as a mentor for emerging talent, leveraging his extensive experience and industry knowledge to guide the board and senior leadership team. We extend our best wishes to Dr. Oberg in his latest appointment and express our gratitude for his continuing contributions to Mynd's success.
在擔任執行董事長的新職位上，奧伯格博士將專注於塑造公司的未來，強調戰略、戰略伙伴關係、收購和公司治理。他還將擔任新興人才的導師，利用其豐富的經驗和行業知識來指導董事會和高級領導團隊。我們向最近任命的奧伯格博士致以最良好的祝願，並對他爲Mynd的成功所做的持續貢獻表示感謝。
ABOUT MYND LIFE SCIENCES INC.
關於 MYND 生命科學公司。
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel drug development, diagnostics and vaccines. MYND is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by unique molecular concepts for the applications of psilocybin analogs for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property.
MYND Life Sciences Inc. 是一家醫療生物技術藥物研發公司，專注於神經藥物和新藥開發、診斷和疫苗。 MYND 正在開發新的生物實體（nBE）和新的化學實體（NCE），並在應用裸蓋菌素類似物克服疾病方面通過獨特的分子概念將自己與其他（生物）製藥公司區分開來。該公司通過嚴格的科學和臨床試驗推動藥物開發，同時努力申請專利和保護其知識產權。
For more information and to subscribe to MYND's mailing list, please visit .
欲了解更多信息並訂閱MYND的郵件列表，請訪問。
CONTACT INFORMATION
聯繫信息
Lih-Ming Tam, CFO
Email: ir@myndsciences.com
Phone: +1 604 813 9795
Web:
譚立明，首席財務官
電子郵件：ir@myndsciences.com
電話：+1 604 813 9795
網頁：
Forward-Looking Statements
前瞻性陳述
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.
本新聞稿包含適用證券立法所指的前瞻性陳述和信息。前瞻性陳述和信息通常可以通過使用 “計劃”、“期望” 或 “不期望”、“預期”、“估計”、“打算”、“預期” 或 “未預見” 或 “相信” 等詞語來識別，或者使用此類詞語和短語的變體或陳述某些行爲、事件或結果 “可能”、“可能” 或 “將” 被採取、發生或實現。前瞻性陳述或信息涉及已知和未知的風險、不確定性和其他因素，這些因素可能導致MYND的實際業績、業績或成就與本新聞稿中包含的前瞻性陳述或信息所表達或暗示的任何未來業績、業績或成就存在重大差異。
Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
與前瞻性信息相關的風險、不確定性和其他因素可能導致實際事件、業績、前景和機會與此類前瞻性信息所表達或暗示的事件、業績、前景和機會存在重大差異。加拿大證券交易所尚未審查本新聞稿內容的充分性或準確性，也不承擔任何責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。